Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III tiragolumab plus atezolizumab versus placebo plus atezolizumab in PD-L1-high NSCLC
2022-502482-17-00Phase 3Completed
- Sponsor
- Roche
- Start
- May 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing tiragolumab + atezolizumab with placebo tiragolumab + atezolizumab (2 arms). Started May 2020; status: completed.
02
Drugs
tiragolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-502482-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502482-17-00.